Proscia has announced a collaboration with Nucleai to expand its precision medicine AI services and help optimize clinical trials and improve treatment decisions.
The collaboration involves integrating Nucleai’s predictive biomarker solutions into Proscia's software platform, Concentriq, as part of its precision medicine AI portfolio. This aims to help create an AI-guided roadmap of patient biopsies, aiding laboratories in optimizing clinical trials and matching patients to effective treatments and enabling pathologists and clinicians to convert data from patient biopsies into actionable insights to support better clinical trial and diagnostic decisions, potentially advancing next-generation treatment modalities such as ADCs, multi-specifics, immunotherapy, and combination therapies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.